Rocket Pharma 
Welcome,         Profile    Billing    Logout  
 9 Products   22 Diseases  9 Products   9 Trials   567 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4885 / Rocket Pharma
ACTRN12608000412336: Part 3 of a study to evaluate the safety of a single dose of increasing amounts of INO-4885 given via a vein to healthy adult male volunteers

Not yet recruiting
1
12
 
Inotek Pharmaceuticals Corporation, Inotek Pharmaceuticals Corporation
No specific health condition being studied - the study is being conducted for safety reasons in healthy male volunteers that do not belong to any target population for the given intervention
 
 
RP-L102 / Rocket Pharma
NCT04248439: Gene Therapy for Fanconi Anemia, Complementation Group A

Active, not recruiting
2
5
US
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
05/26
05/26
NCT04069533 / 2018-002502-31: Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Active, not recruiting
2
7
Europe
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
02/25
02/25
NCT03814408: A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Active, not recruiting
1
2
US
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
12/20
03/22
RP-A501 / Rocket Pharma
NCT06092034: A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Active, not recruiting
2
12
Europe, US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
09/25
09/29
NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Active, not recruiting
1
7
US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
03/25
03/25
REN-001 / Rocket Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4885 / Rocket Pharma
ACTRN12608000412336: Part 3 of a study to evaluate the safety of a single dose of increasing amounts of INO-4885 given via a vein to healthy adult male volunteers

Not yet recruiting
1
12
 
Inotek Pharmaceuticals Corporation, Inotek Pharmaceuticals Corporation
No specific health condition being studied - the study is being conducted for safety reasons in healthy male volunteers that do not belong to any target population for the given intervention
 
 
RP-L102 / Rocket Pharma
NCT04248439: Gene Therapy for Fanconi Anemia, Complementation Group A

Active, not recruiting
2
5
US
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
05/26
05/26
NCT04069533 / 2018-002502-31: Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Active, not recruiting
2
7
Europe
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
02/25
02/25
NCT03814408: A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Active, not recruiting
1
2
US
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
12/20
03/22
RP-A501 / Rocket Pharma
NCT06092034: A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Active, not recruiting
2
12
Europe, US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
09/25
09/29
NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Active, not recruiting
1
7
US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
03/25
03/25
REN-001 / Rocket Pharma
No trials found

Download Options